Director DiMartino Rose initiates 1.0K share position in JEQ at $6.19, near 52-week high of $6.34
DiMartino Rose purchased 1,000 shares of ABRDN JAPAN EQUITY FUND, INC. at $6.19 on 2024-10-02, establishing an initial position in the fund. The transaction occurred within 1.3% of the 52-week high of $6.34, and the stock has appreciated 4.0% over the prior 30 days and 4.7% over 90 days. Across his open-market history, the insider's prior 4 buys averaged a -0.2% 30-day return, providing limited context for evaluating this purchase's timing. As a first purchase by this director, this transaction merits routine disclosure but lacks the pattern or scale to suggest material strategic positioning.
Director DiMartino Rose purchases 1,000 shares of THQ at $21.30; stock up 5.5% in 30 days.
DiMartino Rose, a director, purchased 1,000 shares at $21.30 on 2024-07-16, establishing an initial position in abrdn Healthcare Opportunities Fund. The purchase occurred near the upper end of the 52-week range ($15.33–$21.42), with the stock trading just 1.3% below its 52-week high. This represents the director's 4th open-market transaction based on cross-ticker track record. The stock has appreciated 5.5% over the 30 days following this purchase, suggesting favorable short-term price momentum post-transaction.
Director DiMartino Rose purchases 1,000 shares of abrdn World Healthcare Fund at $13.31 on 2024-07-16
DiMartino Rose, a director of abrdn World Healthcare Fund, initiated a new position in the fund by purchasing 1,000 shares at $13.31 on 2024-07-16, representing the director's first holdings in the security. The purchase occurs with the stock trading at $13.05 currently, representing a modest decline of -7.5% from the 52-week high of $14.11, while the fund has appreciated 3.2% over the 90-day period. This transaction marks the director's fourth open-market purchase across all tickers in the insider's cross-ticker track record, though without prior same-ticker history, the broader pattern of accumulation across securities is the sole quantifiable context available.
Director DiMartino Rose purchases 1,000 shares of HQH at $18.88; stock up 9.0% in 30 days.
DiMartino Rose, a director of abrdn Healthcare Investors, acquired 1,000 shares at $18.88 on 2024-07-16, establishing an initial position in the fund. The purchase occurred near the 52-week high of $18.86, with the stock trading up 9.0% over the prior 30 days and 16.4% over 90 days, suggesting recent momentum in the asset class. This marks the director's fourth open-market buy across his cross-ticker track record, though this appears to be his first position in HQH specifically. The timing and context merit observation of whether the director's conviction persists through future filings.
Director DiMartino Rose buys 1,000 shares of HQL at $15.53; first purchase in this holding.
DiMartino Rose purchased 1,000 shares at $15.53 on 2024-07-16, establishing an initial position in abrdn Life Sciences Investors. The purchase occurred near the 52-week high of $15.46, with the stock having gained 10.2% over 30 days and 17.7% over 90 days prior to the transaction. The insider's cross-ticker track record shows 3 prior buys, though no same-ticker history exists to assess prior patterns specific to HQL. The current price of $15.07 reflects a modest -2.5% decline from the 52-week high, indicating the stock has faced slight headwinds since the transaction date.
